Literature DB >> 11279628

Acute monoblastic leukemia with t(8;16): a distinct clinicopathologic entity; report of a case and review of the literature.

T Sun1, E Wu.   

Abstract

We report a case of acute monoblastic leukemia with t(8;16) in a 71-year-old man who had rapid rise of leukocyte counts from 20.3 x 10(9)/l to 62.7 x 10(9)/l in two weeks. The peripheral blood showed many granular promonocytes that led to the consideration of acute promyelocytic leukemia of the hypogranular variant. The bone marrow, however, revealed mainly monoblasts with erythrophagocytosis. Cytogenetic study finally confirmed the diagnosis of acute monoblastic leukemia with t(8;16). The patient died three days after admission. The demonstration of these two characteristic features of this subtype, granular promonocytes and erythrophagocytosis by monoblasts, separately, in the peripheral blood and bone marrow is unusual and misleading. This cytogenetic abnormality can be demonstrated only in M5 and M4 with characteristic clinical features of disseminated intravascular coagulation, extramedullary involvement, and poor prognosis. Although it is not a common disease, this specific subtype of acute myelogenous leukemia is consistently associated with a specific cytogenetic marker, thus it should be considered a distinct clinicopathologic entity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11279628     DOI: 10.1002/1096-8652(200103)66:3<207::aid-ajh1046>3.0.co;2-q

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  4 in total

Review 1.  Molecular biology in acute leukemia.

Authors:  Mireia Camós; Dolors Colomer
Journal:  Clin Transl Oncol       Date:  2006-08       Impact factor: 3.405

2.  MOZ (MYST3, KAT6A) inhibits senescence via the INK4A-ARF pathway.

Authors:  B N Sheikh; B Phipson; F El-Saafin; H K Vanyai; N L Downer; M J Bird; A J Kueh; R E May; G K Smyth; A K Voss; T Thomas
Journal:  Oncogene       Date:  2015-03-16       Impact factor: 9.867

3.  MOZ regulates B-cell progenitors and, consequently, Moz haploinsufficiency dramatically retards MYC-induced lymphoma development.

Authors:  Bilal N Sheikh; Stanley C W Lee; Farrah El-Saafin; Hannah K Vanyai; Yifang Hu; Swee Heng Milon Pang; Stephanie Grabow; Andreas Strasser; Stephen L Nutt; Warren S Alexander; Gordon K Smyth; Anne K Voss; Tim Thomas
Journal:  Blood       Date:  2015-01-20       Impact factor: 22.113

4.  [Acute myeloid leukemia and translocation (8; 16) (p11; p13), the first Moroccan case of a distinct clinical-biological entity].

Authors:  Adiba Bakkali; Mouna Lemchaheb; Nezha Had; Hind Dehbi; Said Benchekroun; Asma Quessar
Journal:  Pan Afr Med J       Date:  2015-06-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.